Innova Biosciences Introduces The FlexLISA kit
Kit enables flexibility in development and optimization of ELISA assays
Cambridge, UK, 09 May 2017: Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, today announced it has introduced the FlexLISA® kit, providing a flexible tool for development and optimization of sandwich ELISA assays.
The FlexLISA kit allows researchers to covalently conjugate up to 3 capture and 3 detection antibodies using Innova’s Lightning-Link® technology, with any antibody of their choice. As each Lightning-Link kit within the FlexLISA kit contains 3 reactions, multiple conjugation reactions can be run at the same time.
The FlexLISA kit has been designed to allow fast and reliable sandwich ELISA assay development, screening of antibody pairs and ELISA assay optimization, for detection of the presence of any antigen with a high affinity for any antibody pair in complex samples (serum, plasma, urine, etc.). The kit reduces costs as the 96 strip well-plate is pre-coated with biotin to bind capture antibody conjugates with high affinity, so less capture antibody (up to 40 times less) is required compared to a standard ELISA. Researchers also save time, as the FlexLISA assay is a one-step protocol requiring only an hour of incubation time.
Anna Sereni, Head of R&D at Innova Biosciences, commented: “The FlexLISA kit provides researchers with optimum flexibility, and is ideal for quick and reliable ELISA assay development. This is a valuable addition to Innova’s product offering.”
For more information please visit: https://www.innovabiosciences.com/flexlisa/flexlisa.html
ENDS
Media contact
Katie Odgaard, Zyme Communications
Email: katie.odgaard@zymecommunications.com
Phone: +44 (0)7787 502 947
About Innova Biosciences Limited
Innova Biosciences are world leading experts in easy-to-use, cutting-edge bioconjugation technologies and services. The Company has the flexibility to support scientists from academia through to commercial manufacturing, developing and supplying reagent products to make science easier, both off-the shelf and to customer specification. Innova’s products are based on its antibody and protein labelling technology, nanoparticle and oligonucleotide labelling and phosphate detection enzyme assay technologies.
All of Innova Biosciences’ product ranges are of the highest quality and are designed to streamline R&D and manufacturing processes, whilst also reducing overall project costs by cutting expenses associated with e.g. material waste, in-house equipment and staff time, providing increased return on investment compared to traditional methods.
Innova Biosciences’ ever expanding portfolio, including the Lightning-Link®, InnovaCoat® and Thunder-Link® brands, is available to research laboratories, pharmaceutical, biotechnology and diagnostic companies worldwide.
Innova Biosciences is a privately held company and was founded in 2002.
Cambridge, UK, 09 May 2017: Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, today announced it has introduced the FlexLISA® kit, providing a flexible tool for development and optimization of sandwich ELISA assays.
The FlexLISA kit allows researchers to covalently conjugate up to 3 capture and 3 detection antibodies using Innova’s Lightning-Link® technology, with any antibody of their choice. As each Lightning-Link kit within the FlexLISA kit contains 3 reactions, multiple conjugation reactions can be run at the same time.
The FlexLISA kit has been designed to allow fast and reliable sandwich ELISA assay development, screening of antibody pairs and ELISA assay optimization, for detection of the presence of any antigen with a high affinity for any antibody pair in complex samples (serum, plasma, urine, etc.). The kit reduces costs as the 96 strip well-plate is pre-coated with biotin to bind capture antibody conjugates with high affinity, so less capture antibody (up to 40 times less) is required compared to a standard ELISA. Researchers also save time, as the FlexLISA assay is a one-step protocol requiring only an hour of incubation time.
Anna Sereni, Head of R&D at Innova Biosciences, commented: “The FlexLISA kit provides researchers with optimum flexibility, and is ideal for quick and reliable ELISA assay development. This is a valuable addition to Innova’s product offering.”
For more information please visit: https://www.innovabiosciences.com/flexlisa/flexlisa.html
ENDS
Media contact
Katie Odgaard, Zyme Communications
Email: katie.odgaard@zymecommunications.com
Phone: +44 (0)7787 502 947
About Innova Biosciences Limited
Innova Biosciences are world leading experts in easy-to-use, cutting-edge bioconjugation technologies and services. The Company has the flexibility to support scientists from academia through to commercial manufacturing, developing and supplying reagent products to make science easier, both off-the shelf and to customer specification. Innova’s products are based on its antibody and protein labelling technology, nanoparticle and oligonucleotide labelling and phosphate detection enzyme assay technologies.
All of Innova Biosciences’ product ranges are of the highest quality and are designed to streamline R&D and manufacturing processes, whilst also reducing overall project costs by cutting expenses associated with e.g. material waste, in-house equipment and staff time, providing increased return on investment compared to traditional methods.
Innova Biosciences’ ever expanding portfolio, including the Lightning-Link®, InnovaCoat® and Thunder-Link® brands, is available to research laboratories, pharmaceutical, biotechnology and diagnostic companies worldwide.
Innova Biosciences is a privately held company and was founded in 2002.